Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CDNA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDNA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Hanna | $693,269 | $0 | $5,622,638 | $0 | $852,515 | $0 | $11,277 | $7,179,699 |
| President and Chief Executive Officer | ||||||||
| Keith Kennedy | 587,606 | 0 | 2,162,552 | 0 | 430,260 | 0 | 38,813 | 3,219,231 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Abhishek Jain | 282,100 | 0 | 1,557,034 | 0 | 309,526 | 0 | 489,274 | 2,637,934 |
| Former Chief Financial Officer | ||||||||
| Jessica Meng | 485,414 | 0 | 1,730,053 | 0 | 353,683 | 0 | 10,230 | 2,579,380 |
| Chief Commercial Officer | ||||||||
| Jeffrey Novack | 361,923 | 0 | 648,758 | 0 | 216,394 | 0 | 12,477 | 1,239,552 |
| General Counsel and Secretary | ||||||||
| Nathan Smith | 141,539 | 0 | 724,200 | 0 | 91,643 | 0 | 10,577 | 967,959 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Hanna | $7,179,699 | — | — | — |
| Keith Kennedy | 3,219,231 | — | — | — |
| Abhishek Jain | 2,637,934 | — | — | — |
| Jessica Meng | 2,579,380 | — | — | — |
| Jeffrey Novack | 1,239,552 | — | — | — |
| Nathan Smith | 967,959 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Novack | Secretary and General Counsel | 2026-05-01 | D | 2,873 | $22 | $61,770 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-05-05 | D | 2,688 | 21 | 55,581 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 4,086 | 21 | 85,698 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 6,484 | 20 | 128,978 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 100 | 29 | 2,900 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 15,676 | 8 | 128,543 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 39,900 | 8 | 327,180 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 706 | 8 | 5,789 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 13,618 | 8 | 111,668 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 13,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 39,900 | 29 | 1,166,836 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-04 | — | 806 | — | — | 1 insider, 2 accrual rows | ||
| John Walter Hanna JR | Director | 2026-06-04 | D | 15,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 4,835 | 24 | 116,045 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 100 | 8 | 820 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-06-06 | D | 1,292 | 22 | 28,359 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-11 | D | 21,998 | 24 | 528,443 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | D | 12,103 | 23 | 279,728 | Common | Form 4 ↗ |
| R. Bryan Riggsbee | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Suresh Gunasekaran | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| George W. Bickerstaff, III | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-15 | D | 17,683 | 24 | 424,877 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-07-01 | D | 997 | 29 | 29,162 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-07-01 | D | 2,930 | 29 | 85,703 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-01 | D | 8,511 | 29 | 248,947 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-07-01 | D | 2,411 | 29 | 70,522 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-07-02 | A | 1,746 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 100 | 37 | 3,655 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 5,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 7,606 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | A | 118,000 | 8 | 967,600 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 16,048 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 118,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 7,606 | 21 | 156,379 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 28,679 | 36 | 1,036,588 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 16,048 | 14 | 227,721 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 68,000 | 39 | 2,652,932 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 5,125 | 8 | 40,795 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 50,000 | 36 | 1,805,705 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Novack | Secretary and General Counsel | 2026-05-01 | D | 2,873 | $22 | $61,770 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-05-05 | D | 2,688 | 21 | 55,581 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 4,086 | 21 | 85,698 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 6,484 | 20 | 128,978 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 100 | 29 | 2,900 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 15,676 | 8 | 128,543 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 39,900 | 8 | 327,180 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 706 | 8 | 5,789 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 13,618 | 8 | 111,668 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 13,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 39,900 | 29 | 1,166,836 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 15,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 4,835 | 24 | 116,045 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | D | 706 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-04 | A | 100 | 8 | 820 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-06-06 | D | 1,292 | 22 | 28,359 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-11 | D | 21,998 | 24 | 528,443 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | D | 12,103 | 23 | 279,728 | Common | Form 4 ↗ |
| R. Bryan Riggsbee | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Suresh Gunasekaran | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| George W. Bickerstaff, III | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-06-15 | D | 17,683 | 24 | 424,877 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-07-01 | D | 997 | 29 | 29,162 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-07-01 | D | 2,930 | 29 | 85,703 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-01 | D | 8,511 | 29 | 248,947 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-07-01 | D | 2,411 | 29 | 70,522 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-07-02 | A | 1,746 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 100 | 37 | 3,655 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 5,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 7,606 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | A | 118,000 | 8 | 967,600 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 16,048 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 118,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 7,606 | 21 | 156,379 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 28,679 | 36 | 1,036,588 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 16,048 | 14 | 227,721 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 68,000 | 39 | 2,652,932 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 5,125 | 8 | 40,795 | Common | Form 4 ↗ |
| John Walter Hanna JR | Director | 2026-07-16 | D | 50,000 | 36 | 1,805,705 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Abhishek Jain | RSU | 2025-03-23 | — | — | 55,580 | — | $1,557,034 |
| Keith Kennedy | RSU | 2025-03-23 | — | — | 77,195 | — | 2,162,552 |
| Jessica Meng | RSU | 2025-03-23 | — | — | 61,756 | — | 1,730,053 |
| Nathan Smith | RSU | 2025-08-07 | — | — | 42,000 | — | 724,200 |
| John Hanna | RSU | 2025-03-23 | — | — | 200,706 | — | 5,622,638 |
| Jeffrey Novack | RSU | 2025-03-23 | — | — | 23,158 | — | 648,758 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Abhishek Jain | $1,557,034 | $0 | $0 | 0.0% |
| Keith Kennedy | 2,162,552 | 0 | 0 | 0.0% |
| Jessica Meng | 1,730,053 | 0 | 0 | 0.0% |
| Nathan Smith | 724,200 | 0 | 0 | 0.0% |
| John Hanna | 5,622,638 | 0 | 0 | 0.0% |
| Jeffrey Novack | 648,758 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Abhishek Jain | PSU | 72,717 | — | $1,369,988 |
| Keith Kennedy | PSU | 52,575 | — | 990,513 |
| Abhishek Jain | PSU | 42,550 | — | 801,642 |
| Jessica Meng | Option | 51,898 | 29.43 | — |
| Abhishek Jain | PSU | 23,820 | — | 448,769 |
| John Hanna | Option | 408,745 | 8.2 | — |
| John Hanna | PSU | 86,017 | — | 1,620,560 |
| John Hanna | PSU | 365,853 | — | 6,892,671 |
| Keith Kennedy | PSU | 77,195 | — | 1,454,354 |
| Jessica Meng | PSU | 61,756 | — | 1,163,483 |
| Jeffrey Novack | PSU | 27,804 | — | 523,827 |
| Nathan Smith | PSU | 18,000 | — | 339,120 |
| Jeffrey Novack | PSU | 9,925 | — | 186,987 |
| Jeffrey Novack | PSU | 2,913 | — | 54,881 |
| Abhishek Jain | PSU | 637 | — | 12,001 |
| Abhishek Jain | PSU | 3,750 | — | 70,650 |
| Jeffrey Novack | PSU | 3,750 | — | 70,650 |
| Abhishek Jain | PSU | 5,537 | — | 104,317 |
| Abhishek Jain | PSU | 500 | — | 9,420 |
| Nathan Smith | PSU | 42,000 | — | 791,280 |
| Keith Kennedy | PSU | 33,083 | — | 623,284 |
| John Hanna | PSU | 200,706 | — | 3,781,301 |
| Abhishek Jain | PSU | 55,580 | — | 1,047,127 |
| Jeffrey Novack | PSU | 23,158 | — | 436,297 |
| Jeffrey Novack | PSU | 5,000 | — | 94,200 |
| Jessica Meng | PSU | 26,467 | — | 498,638 |
| Jessica Meng | PSU | 39,432 | — | 742,899 |
| Jeffrey Novack | PSU | 1,787 | — | 33,667 |
| Abhishek Jain | Option | 12,863 | 15.66 | — |
| Abhishek Jain | Option | 12,604 | 18.47 | — |
| Abhishek Jain | Option | 1,042 | 24.07 | — |
| Jeffrey Novack | Option | 348 | 26.29 | — |
| Keith Kennedy | Option | 69,198 | 29.43 | — |
| Abhishek Jain | Option | 212 | 32.55 | — |
| Jeffrey Novack | Option | 179 | 37.25 | — |
Our executive compensation program is intended to help us achieve and foster a goal-oriented, highly-motivated management team with a clear understanding of our business objectives and shared corporate values. To this end, the Compensation and Human Capital Committee believes that our executive compensation program should provide compensation that: attracts and retains the best executive talent; appropriately aligns our business objectives and stockholder interests; maintains a reasonable balance across types and purposes of compensation; motivates our executive officers to achieve our annual and long-term strategic goals and rewards performance based on the attainment of such goals; appropriately considers risk and reward in the context of our business environment and long-range business plans; recognizes individual value and contributions to our success; considers, but does not exclusively rely upon, competitive market data; and assists with the design and structure of our overall equity compensation practices.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 39,387,247 | 1,905,070 | 20,705 | 95.34% | Passed |
| 2025 | 2025-06-12 | 40,012,994 | 3,694,527 | 23,851 | 91.55% | Passed |
| 2024 | 2024-06-13 | 38,902,912 | 1,639,617 | 40,225 | 95.96% | Passed |
| 2023 | 2023-06-15 | 38,609,980 | 1,801,445 | 59,166 | 95.54% | Passed |
| 2022 | 2022-06-15 | 44,699,515 | 1,700,604 | 24,752 | 96.33% | Passed |
| 2021 | 2021-06-15 | 41,311,677 | 3,896,382 | 34,628 | 91.31% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 95.34%a |
| 2025 | 2025-06-12 | 91.55%b |
| 2024 | 2024-06-13 | 95.96%c |
a. Approved under the standard stated in the filing — “2, the abstention will have the same effect as a vote AGAINST the proposal.”.
b. Approved under the standard stated in the filing — “1 will be determined by a plurality vote (see the next question below for an explanation of what a plurality vote means), abstentions will have no impact on the outcome of such proposal as long as a quorum exists.”.
c. Approved under the standard stated in the filing — “1 will be determined by a plurality vote (see the next question below for an explanation of what a plurality vote means), abstentions will have no impact on the outcome of such proposal as long as a quorum exists.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 48 : 1 |
|---|---|
| CEO total compensation | $7,179,699 |
| Median employee compensation | $148,417 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Suresh GunasekaranIndependent · Newly elected | $9,647 | $399,990 | $0 | $0 | $0 | $409,637 |
| Michael D. GoldbergIndependent · Board Chair · Compensation and Human Capital | 138,736 | 224,995 | 0 | 0 | 0 | 363,731 |
| Christine M. CournoyerIndependent · Audit and Finance · Compensation and Human Capital (Chair) | 72,747 | 224,995 | 0 | 0 | 0 | 297,742 |
| George W. Bickerstaff, IIIIndependent · Audit and Finance · Compensation and Human Capital | 70,247 | 224,995 | 0 | 0 | 0 | 295,242 |
| R. Bryan RiggsbeeIndependent · Audit and Finance (Chair) | 67,747 | 224,995 | 0 | 0 | 0 | 292,742 |
| Hannah A. Valantine, M.DIndependent · Technology and Innovation | 62,747 | 224,995 | 0 | 0 | 0 | 287,742 |
| Arthur A. TorresIndependent · Governance and Nominating | 57,747 | 224,995 | 0 | 0 | 0 | 282,742 |
| Peter Maag, Ph.DIndependent · Technology and Innovation · Governance and Nominating | 52,747 | 224,995 | 0 | 0 | 0 | 277,742 |
| Fred E. Cohen, M.D., D. PhilIndependent · Governance and Nominating | 52,747 | 224,995 | 0 | 0 | 0 | 277,742 |
| William A. HagstromIndependent · Not standing for re-election · Departed during FY | 24,025 | — | 0 | 0 | 0 | 24,025 |
| John W. HannaEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $225,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $609,137 |
| Equity awards (grant-date value) | $2,199,950 |
| All other compensation | $0 |
| Total cost of the board | $2,809,087 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies CareDx names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including CareDx.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera, Inc. | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 3 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 4 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 5 | Adaptive Biotechnologies Corp. | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 6 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 7 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 8 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 9 | Castle Biosciences, Inc. | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 10 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 11 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 12 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 13 | Pacific Biosciences of California, | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| CareDx | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| Adaptive Biotechnologies Corp. | 100% | RSU 50 · PSU 50 | No | Semler Brossy Consulting Group, LLC |
| Castle Biosciences, Inc. | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Pacific Biosciences of California, | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Hanna | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 2 | Section 01, Keith Kennedy | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 3,219,231. Filing ↗machine: t113 · r5 · c9 · span 1906621–1906630 |
| 3 | Section 01, Abhishek Jain | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 2,637,934. Filing ↗machine: t113 · r11 · c9 · span 1943874–1943883 |
| 4 | Section 01, Jessica Meng | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 2,579,380. Filing ↗machine: t113 · r7 · c9 · span 1919032–1919041 |
| 5 | Section 01, Jeffrey Novack | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 1,239,552. Filing ↗machine: t113 · r9 · c9 · span 1931460–1931469 |
| 6 | Section 01, Nathan Smith | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Summary Compensation Table” · page 71. As printed: 967,959. Filing ↗machine: t113 · r14 · c9 · span 1962356–1962363 |
| 7 | Section 03, Abhishek Jain RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r8 · c1 · span 1807789–1807795 |
| 8 | Section 03, Keith Kennedy RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r5 · c1 · span 1795547–1795553 |
| 9 | Section 03, Jessica Meng RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r6 · c1 · span 1799620–1799626 |
| 10 | Section 03, Nathan Smith RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r9 · c1 · span 1811947–1811953 |
| 11 | Section 03, John Hanna RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r4 · c1 · span 1791478–1791485 |
| 12 | Section 03, Jeffrey Novack RSU | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “EBITDA” · grants of plan-based awards table. Filing ↗machine: t108 · r7 · c1 · span 1803696–1803702 |
| 13 | Section 07, pay ratio | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “CEO Pay Ratio”. As printed: 48 : 1. Filing ↗ |
| 14 | Section 08, Suresh Gunasekaran | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 409,637. Filing ↗machine: t54 · r12 · c4 · span 1027224–1027231 |
| 15 | Section 08, Michael D. Goldberg | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 363,731. Filing ↗machine: t54 · r3 · c4 · span 1001999–1002006 |
| 16 | Section 08, Christine M. Cournoyer | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 297,742. Filing ↗machine: t54 · r6 · c4 · span 1010229–1010236 |
| 17 | Section 08, George W. Bickerstaff, III | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 295,242. Filing ↗machine: t54 · r4 · c4 · span 1004743–1004750 |
| 18 | Section 08, R. Bryan Riggsbee | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 292,742. Filing ↗machine: t54 · r9 · c4 · span 1018843–1018850 |
| 19 | Section 08, Hannah A. Valantine, M.D | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 287,742. Filing ↗machine: t54 · r11 · c4 · span 1024333–1024340 |
| 20 | Section 08, Arthur A. Torres | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 282,742. Filing ↗machine: t54 · r10 · c4 · span 1021582–1021589 |
| 21 | Section 08, Peter Maag, Ph.D | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 277,742. Filing ↗machine: t54 · r8 · c4 · span 1016104–1016111 |
| 22 | Section 08, Fred E. Cohen, M.D., D. Phil | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 277,742. Filing ↗machine: t54 · r5 · c4 · span 1007493–1007500 |
| 23 | Section 08, William A. Hagstrom | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 24,025. Filing ↗machine: t54 · r7 · c1 · span 1011491–1011497 |
| 24 | Section 08, John W. Hanna | DEF 14A | 2026-04-27 | 0001217234-26-000028 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 02, Jeffrey Novack 2026-05-01 | Form 4 | 2026-05-04 | 0002019976-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Jeffrey Novack 2026-05-05 | Form 4 | 2026-05-06 | 0002019976-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Arthur A. Torres 2026-05-14 | Form 4 | 2026-05-18 | 0001251737-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Arthur A. Torres 2026-05-14 | Form 4 | 2026-05-18 | 0001251737-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-08 | 0001781127-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, John Walter Hanna JR 2026-06-04 | Form 4 | 2026-06-30 | 0001781127-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Jeffrey Novack 2026-06-06 | Form 4 | 2026-06-09 | 0002019976-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, John Walter Hanna JR 2026-06-11 | Form 4 | 2026-06-15 | 0001781127-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michael D. Goldberg 2026-06-12 | Form 4 | 2026-06-16 | 0001366412-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Christine M. Cournoyer 2026-06-12 | Form 4 | 2026-06-16 | 0001180466-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Fred E. Cohen 2026-06-12 | Form 4 | 2026-06-16 | 0001339358-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Hannah Valantine 2026-06-12 | Form 4 | 2026-06-16 | 0001855608-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Hannah Valantine 2026-06-12 | Form 4 | 2026-06-16 | 0001855608-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, R. Bryan Riggsbee 2026-06-12 | Form 4 | 2026-06-16 | 0001621899-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Suresh Gunasekaran 2026-06-12 | Form 4 | 2026-06-16 | 0002093388-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, George W. Bickerstaff, III 2026-06-12 | Form 4 | 2026-06-16 | 0001329646-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, John Walter Hanna JR 2026-06-15 | Form 4 | 2026-06-17 | 0001781127-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Jeffrey Novack 2026-07-01 | Form 4 | 2026-07-02 | 0002019976-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Keith Kennedy 2026-07-01 | Form 4 | 2026-07-02 | 0001543503-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, John Walter Hanna JR 2026-07-01 | Form 4 | 2026-07-06 | 0001781127-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Jessica Meng 2026-07-01 | Form 4 | 2026-07-02 | 0002036499-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael D. Goldberg 2026-07-02 | Form 4 | 2026-07-07 | 0001366412-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, John Walter Hanna JR 2026-07-16 | Form 4 | 2026-07-17 | 0001781127-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, John Walter Hanna JR 2026-07-16 | Form 4 | 2026-07-17 | 0001781127-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, John Walter Hanna JR 2026-07-16 | Form 4 | 2026-07-17 | 0001781127-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Hannah Valantine 2026-07-16 | Form 4 | 2026-07-17 | 0001855608-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, John Walter Hanna JR 2026-07-16 | Form 4 | 2026-07-17 | 0001781127-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 06, 2026 vote | Form 8-K | 2026-06-15 | 0001217234-26-000036 | Item 5.07 · say-on-pay result. As reported: 95.34% (votes for as printed: 39,387,247). Filing ↗ |
| 71 | Section 06, 2025 vote | Form 8-K | 2025-06-12 | 0001193125-25-139978 | Item 5.07 · say-on-pay result. As reported: 91.55% (votes for as printed: 40,012,994). Filing ↗ |
| 72 | Section 06, 2024 vote | Form 8-K | 2024-06-18 | 0001217234-24-000071 | Item 5.07 · say-on-pay result. As reported: 95.96% (votes for as printed: 38,902,912). Filing ↗ |
| 73 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 74 | Section 09b board cost (computed) | Computed | — | computed | Cash 609,137 + equity 2,199,950 + all other 0 = 2,809,087, summed across the director compensation table rows.machine: formula: Σ = 2,809,087 |
| 75 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 76 | Twist Bioscience Corporation, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 77 | TransMedics Group, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150357 | CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179 |
| 78 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 79 | Adaptive Biotechnologies Corp., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies Corp.'s own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 80 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 81 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 82 | CareDx (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 83 | Castle Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001628280-26-024166 | CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096 |
| 84 | Fulgent Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 85 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997 |
| 86 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 87 | Pacific Biosciences of California,, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California,'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 88 | Section 10a, Adaptive Biotechnologies Corp. reciprocity | DEF 14A | — | 0001193125-26-177409 | Adaptive Biotechnologies Corp. names CareDx in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 89 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |
| 90 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |
| 91 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |
| 92 | Section 10a, Pacific Biosciences of California, reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California,'s most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |
| 93 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc. names CareDx in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 94 | Section 10a, TransMedics Group reciprocity | DEF 14A | — | 0001193125-26-150357 | TransMedics Group's most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |
| 95 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc. names CareDx in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 96 | Section 10a, Fulgent Genetics, Inc. reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics, Inc. names CareDx in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 97 | Section 10a, Castle Biosciences, Inc. reciprocity | DEF 14A | — | 0001628280-26-024166 | Castle Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include CareDx. Filing ↗ |